BG Medicine Announces Obtaining CE Mark, Launch of Automated BGM Galectin-3 Test
BG Medicine, Inc. (Nasdaq: BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the first automated version of the BGM Galectin-3(r) blood test has obtained a CE Mark, an important step in the company's commercial strategy.
The BGM Galectin-3 test will be distributed through bioMerieux's VIDAS(r) immunoassay platform which includes about 27,000 installed instruments worldwide. bioMerieux is one of four diagnostic instrument manufacturers partnering with BG Medicine to commercialize automated versions of the BGM Galectin-3 test, and the first to obtain a CE Mark. bioMerieux is preparing a phased launch of the test in Europe and in certain other territories that recognize the CE Mark.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.